Ascentage Pharma

Ascentage Pharma is a clinical-stage biopharmaceutical company based in Suzhou, China, that discovers and develops novel small-molecule targeted therapies for cancers and chronic hepatitis B. The publicly traded enterprise focuses on therapeutics addressing protein-protein interactions and apoptosis pathways to treat drug-resistant conditions, such as chronic myeloid leukemia and solid tumors. Operating globally with research facilities in the United States and Australia, the firm currently advances a diverse pipeline of over nine clinical-stage drug candidates. The company commercializes its approved treatments and out-licenses its pipeline through strategic partnerships with major pharmaceutical corporations, including Takeda Pharmaceutical Company and Innovent Biologics. In June 2024, the organization secured a $100 million upfront payment from Takeda through an exclusive global licensing option agreement for its lead leukemia drug, Olverembatinib. Ascentage Pharma was founded in 2009 by Dajun Yang, Shaomeng Wang, and Ming Guo.